Bone marrow sympathetic activation regulates post-myocardial infarction megakaryocyte expansion but not platelet production

2019 ◽  
Vol 513 (1) ◽  
pp. 99-104 ◽  
Author(s):  
Wenwen Fu ◽  
Guannan Meng ◽  
Xiaomeng Yang ◽  
Lilei Yu ◽  
Hong Jiang
2010 ◽  
Vol 299 (1) ◽  
pp. H125-H133 ◽  
Author(s):  
John J. Graham ◽  
Warren D. Foltz ◽  
Andrea K. Vaags ◽  
Michael R. Ward ◽  
Yuesong Yang ◽  
...  

Magnetic resonance imaging (MRI) can track progenitor cells following direct intramyocardial injection. However, in the vast majority of post-myocardial infarction (MI) clinical trials, cells are delivered by the intracoronary (IC) route, which results in far greater dispersion within the myocardium. Therefore, we assessed whether the more diffuse distribution of cells following IC delivery could be imaged longitudinally with MRI. In 11 pigs (7 active, 4 controls), MI was induced by 90-min balloon occlusion of the left anterior descending coronary artery. Seven (0) days [median (interquartile range)] following MI, bone marrow progenitor cells (BMCs) were colabeled with an iron-fluorophore and a cell viability marker and delivered to the left anterior descending coronary artery distal to an inflated over-the-wire percutaneous transluminal coronary angioplasty balloon. T2*-weighted images were used to assess the location of the magnetically labeled cells over a 6-wk period post-MI. Immediately following cell delivery, hypointensity characteristic of the magnetic label was observed in the infarct border rather than within the infarct itself. At 6 wk, the cell signal hypointensity persisted, albeit with significantly decreased intensity. BMC delivery resulted in significant improvement in infarct volume and ejection fraction (EF): infarct volume in cell-treated animals decreased from 7.1 ± 1.5 to 4.9 ± 1.0 ml ( P < 0.01); infarct volume in controls was virtually unchanged at 4.64 ± 2.1 to 4.39 ± 2.1 ml ( P = 0.7). EF in cell-treated animals went from 30.4 ± 5.2% preinjection to 34.5 ± 2.5% 6 wk postinjection ( P = 0.013); EF in control animals went from 34.3 ± 4.7 to 31.9 ± 6.8% ( P = 0.5). Immunohistochemical analysis revealed intracellular colocalization of the iron fluorophore and cell viability dye with the labeled cells continuing to express the same surface markers as at baseline. MRI can track the persistence and distribution of magnetically labeled BMCs over a 6-wk period following IC delivery. Signal hypointensity declines with time, particularly in the first week following delivery. These cells maintain their original phenotype during this time course. Delivery of these cells appears safe and results in improvement in infarct size and left ventricular ejection fraction.


PLoS ONE ◽  
2020 ◽  
Vol 15 (8) ◽  
pp. e0237401
Author(s):  
Xiaoyin Wang ◽  
Lourdes I. Chacon ◽  
Ronak Derakhshandeh ◽  
Hilda J. Rodriguez ◽  
Daniel D. Han ◽  
...  

2019 ◽  
Author(s):  
Xiaoyin Wang ◽  
Ronak Derakhshandeh ◽  
Hilda J. Rodriguez ◽  
Daniel D. Han ◽  
Dmitry S. Kostyushev ◽  
...  

AbstractImplantation of bone marrow-derived cells (BMCs) into mouse hearts post-myocardial infarction (MI) limits cardiac functional decline. However, clinical trials of post-MI BMC therapy have yielded conflicting results. While most laboratory experiments use healthy BMC donor mice, clinical trials use post-MI autologous BMCs. Post-MI mouse BMCs are therapeutically impaired, due to inflammatory changes in BMC composition. Thus, therapeutic efficacy of the BMCs progressively worsens after MI but recovers as donor inflammatory response resolves. The availability of post-MI patient BM mononuclear cells (MNCs) from the TIME and LateTIME clinical trials enabled us to test if human post-MI MNCs undergo a similar period of impaired efficacy. We hypothesized that MNCs from TIME trial patients would be less therapeutic than healthy human donor MNCs when implanted into post-MI mouse hearts, and that therapeutic properties would be restored in MNCs from LateTIME trial patients. Post-MI SCID mice received MNCs from healthy donors, TIME patients, or LateTIME patients. Cardiac function improved considerably in the healthy donor group, but neither the TIME nor LateTIME group showed therapeutic effect. Conclusion: post-MI human MNCs lack therapeutic benefits possessed by healthy MNCs, which may partially explain why BMC clinical trials have been less successful than mouse studies.


Sign in / Sign up

Export Citation Format

Share Document